Seagen competitors

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

José E. Almeida is a Brazilian businessman. He has served as the chairman and CEO of Baxter International, Inc. since January 2016. He worked for Tyco Healthcare from 1995 to 2002. He was president of Medical Devices division from October 2006 to June 2011. He served as chairman of the board of directors of Covidien since March 2012 and as the president, chief executive officer and a director since July 2011. He became a director of EMC Corporation on Jan 12, 2015 and resigned on October 30, 2015, due to his election as chairman and CEO of Baxter. In 2015, he worked for The Carlyle Group as an Operating Executive in the Global Healthcare group.

Robert was appointed President and Chief Executive Officer of Cytokinetics in January 2007 and has been a member of our Board of Directors since then. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert has served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. He served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League. Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Robert was a fan of mountain bluegrass music long before it was fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget, as well as his Bernese mountain dog, Baron, on long hikes in the Presidio.

Ryan Spencer is a Board Member at Dynavax Technologies and Chief Executive Officer at Dynavax Technologies and is based in Berkeley, California. He has worked as Senior Director Commercial Operations at Dynavax Technologies; Senior Product Director, HEPLISAV-B at Dynavax Technologies; and Vice President, Corporate Strategy & Commercial Operations at Dynavax Technologies. Ryan attended Universidade Federal de Santa Catarina between 1995 and 1999.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Brad Gray joined NanoString from Genzyme Genetics, the diagnostic services division of Genzyme Corporation, where he was most recently Vice President of Product & Business Development leading the development of molecular diagnostics and partnering activities. Mr. Gray held several strategy and business development roles at the corporate and division levels beginning in 2004 when he joined Genzyme Corporation as Director of Corporate Development. Previously, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company. He holds a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.

Phillip Frost is a Board Member at Ym Biosciences Inc., General Partner at Peregrine Ventures Management Ltd, and Board Member at Protalix Ltd and is based in Miami Beach, Florida. He has worked as Governor at American Stock Exchange; Board Member at COCRYSTAL PHARMA, INC.; and Chairman:Dermatology at Mount Sinai. Phillip works or has worked as TRUSTEE at Frost Nevada Investments Trust, BOARD MEMBER at Shanghai Institute for Advanced Immunochemical Studies, and BOARD MEMBER at Smithsonian Institution. He studied at University of Pennsylvania until 1957, Yeshiva University, and Albert Einstein College of Medicine until 1961.